The FDA recently approved calcipotriene (Sorilux) foam 0.005% for the treatment of plaque psoriasis in patients aged 12 years and older.
Calcipotriene is a synthetic vitamin D3 analogue that is applied twice daily to the scalp and/or body.
You may also like...
Inside the New Psoriasis Guidelines, Part I
What to Know About the Latest Topical Therapy Approved for Psoriasis
The approval was based on data from two 8-week placebo-controlled trials that included patients with mild to moderate psoriasis on the body, as well as 8-week trial that included patients with moderate psoriasis on the scalp.
Application site erythema and pain were the most commonly reported adverse reactions. Patients with hypercalcemia should not receive calcipotriene.